Bifido비피도

Bifido returned to a trailing six-month profit on a net basis but still runs an operating loss, and its share price has fallen sharply over the past year.

Bifido, a KOSDAQ-listed probiotic and health food maker, reported trailing twelve-month revenue of about ₩14.6B and an operating loss of about ₩1.0B as of H1 2026, while net income was positive at about ₩1.8B. The share price closed at ₩2,535 on 20 October 2026, down 30.5% over one year, and the company's market value is about ₩20.7B.

What stands out

• Trailing operating margin is -7%, while net margin is 12.6%, so the reported net profit is not explained by core operations in the data given.
• FY2025 revenue rose 59.3% to about ₩19.7B with a 7.1% operating margin, but FY2025 net income was a small loss of about ₩0.2B.
• The company held about ₩7.6B in cash against ₩10B in borrowings, and trailing free cash flow was negative at about -₩3.0B.
• Valuation metrics are low on the data shown: P/E about 11.2 and P/B about 0.4, with no dividend.
• Filings in 2026 include a disposal of tangible assets and a merger completion report for an asset acquisition and transfer, and the company's rheumatoid arthritis candidate was withdrawn in late 2025 according to the company profile.

What to watch

• The next half-year and annual results, to see whether operating income turns sustainably positive and whether the trailing net profit holds.
• Details of the asset transfer and merger filings, and how they affect the balance sheet and future revenue.
• Foreign ownership, which fell from 1.1% to 0.9% over 60 days, and the share price relative to its 52-week range of ₩2,045 to ₩3,995.